SCHEMBL4408213

SCHEMBL4408213

CC(C)(C)OC(=O)N1CCN2C(=O)c3ccccc3OCC2C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 3/20 0.43
SMARCA2 P51531 1/20 0.43
SMARCA4 P51532 1/20 0.43
PBRM1 Q86U86 1/20 0.43
TP53 P04637 1/20 0.41
SCN9A Q15858 1/20 0.41
HDAC6 Q9UBN7 2/20 0.40
DTYMK P23919 1/20 0.39
GPR119 Q8TDV5 2/20 0.39
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39
CHRM1 P11229 1/20 0.39
CHRM3 P20309 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
HTR2B P41595 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
PDK4 Q16654 1/20 0.39
ABCB1 P08183 1/20 0.39
EGFR P00533 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4410166 0.88 USP30 (0.51) USP30SMARCA2SMARCA4PBRM1HDAC6
SCHEMBL4408792 0.87 TP53 (0.46) USP30SMARCA2SMARCA4PBRM1TP53
SCHEMBL4410917 0.87 USP30 (0.49) USP30SMARCA2SMARCA4PBRM1HDAC6
SCHEMBL4411286 0.87 USP30 (0.44) USP30SMARCA2SMARCA4PBRM1HDAC6
SCHEMBL4409882 0.86 FPR2 (0.43) USP30SMARCA2SMARCA4PBRM1TP53
SCHEMBL4415810 0.86 USP30 (0.42) USP30SMARCA2SMARCA4PBRM1TP53
SCHEMBL4411908 0.86 TP53 (0.46) USP30SMARCA2SMARCA4PBRM1TP53
SCHEMBL4410015 0.86 SCN9A (0.42) USP30SMARCA2SMARCA4PBRM1TP53
SCHEMBL4411051 0.85 USP30 (0.41) USP30SMARCA2SMARCA4PBRM1TP53
SCHEMBL30881516 0.85 GPR119 (0.47) USP30SMARCA2SMARCA4PBRM1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090318412-A1 Tricyclic heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318412-A1 Tricyclic heterocyclic compound and use thereof HTR2C, HTR2A, HTR5A USP30 4369/4885SMARCA2 3907/4885SMARCA4 4157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.